KPMG Highlights Need for Digital Life Science Supply Chains

- The cell and gene therapy (CGT) supply chain faces significant bottlenecks in materials sourcing, logistics, and manufacturing capacity, which is exacerbated by a shortage of skilled personnel. Legacy manufacturing processes are a primary driver of high therapeutic costs, creating an urgent need for more efficient, scalable solutions. - Digital twins are being implemented in biomanufacturing to simulate and optimize complex processes like cell culture and purification, using real-time data to predict outcomes and enhance process resilience. This technology allows for *in silico* experimentation, which reduces the need for costly and time-consuming physical studies and accelerates scale-up from lab to commercial production. - AI and machine learning are increasingly used to optimize bioprocesses by analyzing large datasets to identify critical control points and predict optimal operating conditions. In viral vector development, analytics-powered digital tools are crucial for process modeling and optimization to address quality control challenges. - The global cell and gene therapy CDMO market is projected to grow from $8.07 billion in 2025 to approximately $74.03 billion by 2034. This growth is driven by the need for specialized expertise to manage complex manufacturing processes and navigate regulatory challenges. - Electronic Batch Record (EBR) systems are replacing paper-based documentation to improve data integrity and GMP compliance. These systems integrate with LIMS and Manufacturing Execution Systems (MES) to automate data collection, reduce manual errors, and provide comprehensive audit trails. - A major challenge in viral vector manufacturing is the lack of standardized production platforms, with processes varying significantly even between different serotypes of the same virus. This fragmentation, combined with low yields in purification steps and the need for ultra-low temperature storage, complicates scalable production. - While the CGT market is expanding, the biotech funding climate has become more cautious since a post-pandemic peak in 2021. Investors are now favoring companies with strong scientific foundations and experienced management, leading to larger funding rounds for fewer companies. - Industry 4.0 concepts are being adopted in CGT manufacturing to move from manual, centralized processes to automated, knowledge-driven models. Companies like Cellular Origins are developing robotic platforms to enable scalable and cost-effective advanced therapy manufacturing for CDMOs and therapy developers.